Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp (Nasdaq: OPRX) announced that Mike Rousselle, its vice president of data product, has been named one of the 2022 PM360 ELITE 100 in the Data Miners category. Rousselle is recognized for his work in applying AI and ML in healthcare marketing, streamlining engagement with healthcare providers at the point-of-care. Steve Silvestro, CCO, highlighted Rousselle's role in driving innovation and efficiency in data solutions for life sciences clients. The PM360 ELITE Awards celebrate influential figures in healthcare, with 100 winners selected from over 500 nominations.
OptimizeRx Corp (Nasdaq: OPRX) has announced a share repurchase program authorized by its Board of Directors, allowing the company to buy back up to $20 million of its outstanding common stock. CEO Will Febbo indicated this decision reflects the company's commitment to disciplined capital allocation aimed at enhancing shareholder returns. The repurchase aims to strengthen shareholder value while ensuring sufficient working capital for future growth initiatives, including organic growth and potential M&A activities.
OptimizeRx (Nasdaq: OPRX) announced its participation in the RBC Healthcare Conference on May 17-18, 2022, and the B. Riley Annual Institutional Conference on May 25-26, 2022. The company will partake in a fireside chat at the RBC event on May 18 at 2:05 PM ET, and present at the B. Riley conference on May 26 at 9:30 AM PT. Management will also hold one-on-one meetings at both events. OptimizeRx is a leading provider of point-of-care technology that connects patients and healthcare providers to improve medication adherence.
OptimizeRx Corp. (Nasdaq: OPRX) reported Q1 2022 revenue of $13.7 million, a 22% increase YoY. Gross profit rose 32% to $8.1 million, with gross margins at 59%. Net loss was $3.8 million or $(0.21) per share. The company completed the acquisition of EvinceMed and maintains a strong cash position of $89.0 million. OPRX reaffirms its 2022 revenue outlook of $80 million to $85 million, targeting 31% to 39% growth. The firm is experiencing positive cash flow from operations with a focus on growth through expanding client engagement.
OptimizeRx Corp (Nasdaq: OPRX) announces a conference call on May 4, 2022, at 4:30 p.m. Eastern Time to discuss its first-quarter financial results for the period ending March 31, 2022. A press release with the financial results will precede the call. Participants can join by telephone or webcast, with a replay available for 12 months on the company’s website. OptimizeRx provides point-of-care technology solutions, connecting healthcare providers and patients to enhance medication adherence.
OptimizeRx has announced the acquisition of EvinceMed, enhancing its point-of-care technology solutions to improve access to specialty medications for patients. This strategic acquisition strengthens OptimizeRx's platform, which connects over 700,000 healthcare providers, enabling faster patient access to therapies through process automation. Specialty drugs, while only 2.2% of prescriptions, accounted for over 45% of pharmacy spending in 2019, highlighting a significant market opportunity. The integration aims to increase revenue growth in 2023 and improve workflows for healthcare providers.
FAQ
What is the current stock price of Optimizerx (OPRX)?
What is the market cap of Optimizerx (OPRX)?
